BioSig Technologies, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by BioSig Technologies, Inc. (BSGM) on July 13, 2021. The registrant is incorporated in Delaware and operates on the NASDAQ Capital Market. The report discloses a material event under Item 7.01 (Regulation FD Disclosure) regarding a new clinical evaluation agreement.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document serves as a disclosure of a corporate event rather than a financial performance report.
Material Changes and Events
- New Clinical Agreement: On July 13, 2021, the Company signed an agreement with Medical City North Hills in North Richland Hills, Texas.
- Purpose: The agreement is for the clinical evaluation of the Company's PURE EP technology.
- Disclosure Status: The information is furnished under Regulation FD but is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future performance, or specific risk factors beyond the standard disclaimer that the Company undertakes no obligation to update the attached press release materials.
Investor Verification Checklist
- Verify the specific terms and duration of the agreement with Medical City North Hills in the attached Exhibit 99.1 (Press Release).
- Confirm the current status of the PURE EP technology clinical trials in subsequent filings.
- Review the Company's most recent 10-Q or 10-K for actual financial performance metrics, as this 8-K contains none.